Research programme: corneal graft rejection gene therapy - Oxford Biomedica

Drug Profile

Research programme: corneal graft rejection gene therapy - Oxford Biomedica

Alternative Names: EncorStat; OXB 202

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Keratoplasty rejection

Most Recent Events

  • 04 Dec 2017 corneal graft rejection gene therapy is still in preclinical development for keratoplasty rejection in the United Kingdom (Oxford BioMedica pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Keratoplasty-rejection(Prevention) in United Kingdom (Intraocular, Implant)
  • 17 Feb 2014 Oxford BioMedica regains the full worldwide rights to EncorStat® from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top